Theresa Lambe & Sarah Gilbert

Liverpool School of Tropical Medicine

https://doi.org/10.12688/wellcomeopenres.16522.1

Sumathi Sivapalasingam

Francisca Mutapi

We (NIHR Unit Tackling Infections to benefit Africa (TIBA) at the University of Edinburgh) are funded by the UK National Institutes of Health Research through the Global Health Research Fund. As part of this funding we were instructed to use some of the funding for research to respond to national of global health emergencies

Approved for diagnostic evaluation platform

Brighton and Sussex Medical School

10-20ul serum. Recovered patients. Clinical course must be known. ~ 100 samples.

Health Protection Scotland

Serum samples at least 500ul. Helpful if it's pared as acute and convalescent. N=50.

Reginald Clayton

Serum and Plasma. 1ml vial of urine and oral swabs if available. Male patients moderate and severe

MRC/UKRI rolling funding call

Alex von Kriegsheim

Plasma - 100µl from 600 patients - 12.06.2020 request changed to 500ul for steroid analyes, 60 severe, 60 mild, 80 unifected (unavailable)

Core BBSRC funds. University of Kent funds.

Approved for diagnostic evaluation platform

MRC fellowship and existing industry collaborations

British HIV Association Group

Periodic reports of HIV positive patients. Access to immunology, serology and PCR results. Every 1-3 months. Samples: Serum/plasma 500ul from as many HIV-positive patients as possible.

Roya E Haghihat-Khah

RNA from Oracol or viral throat swabs. RNA or materials from 300 patietns.

University College London

Blood RNA (600ng extracted from tempus tubes) Day 1,3,9 and 28. 300 longitudinal patients.

UKRI funding application depending on sample access

4 million PBMCs from 50 COVID-19 patients with and without Type 2 diabetes at Day 1 and Day 28 (where available). Linked patient metadata including age, gender, disease severity, supportive care received, trial treatments and outcome. Matched for age, gender and disease severity at Day 1.

Salary and lab running costs covered by existing grants. Applying for Diabetes UK COVID-19 Rapid Response for further funding.

University of Liverpool and Liverppol University Hospitals NHS Foundation Trust

Douglas B Kell (PI) Andrew S Davison

Surplus serum and anonymised metadata (age, sex, disease status and other clinical information) collected in Liverpool Clinical Laboratories. Each sample requires a minimum volume of 150ul.

Funding in place for 100 samples. Funding pending for 1000+ samples.

https://doi.org/10.1101/2020.10.08.20209411

Data - analysis of patient data with features suggestive of neurological disease. Determine risk factors for neurological disease. If protocols and ethics allow, detailed questionnaire to be sent to research sites and contact patients for more info re outcome. Samples- CSF (2ml - min of 100ul doable) and serum (2ml). Unsure how many samples may be available.

Funding from NIHR HPRU in EZI

All phenotypic data (biochemical, hematological, immunological data), host genotype data, RNA seq data (D1,3,9 and 28). Viral sequencing data for host genetics and viral sequence.

Quebec provincial government and Fonds de recherche du Quebec - Sante.

Approve for collaboration

Clinical data collected on admission, daily and outcome forms. Differences in outcomes based on ethnicity, co-morbidities, obesity and socio-economic status.

Serum and plasma (5mls) - 200 patients (100 ICU vs 100 non-ICU). Stools (5-10ml) 1000 patients with associated clinical data (cluster 3 - with GI symptoms vs non-GI symptoms). Clinical data - 1000 patients stratified by disease severity and clinical phenotype - with or without diarrhea.

Helmsley Trust, ERC, Scot Government RESAS, BBSCRC, and funds form Scottish Senior Fellowship.

Lance Turtle Julian Hiscox

20-50 respiratory tract swabs from patients with severe COVID-19 and mild/moderate disease respectively.

Zoltan Takats James Kinross Lauren Ford *In combination with Request 47 Dumas

Combined nose and throat swabs, otherwise a throat swab or nasopharyngeal swab alone. As many as possible.

Imperial Biomedical Research Centre.

Marc-Emmanuel Dumas Julian Griffin Zoltan Takats Peter Openshaw *In combination with Request 43 Takats

All 650 patients at 4 timepoints - 2600 samples. Plasma (or serum) 375ul per sample. Urine 275ul per sample. Stool 500mg per sample. Swab metabolomics - Prof Takats application (Request 43)

Imperial Biomedical Research Centre.

University of Liverpool University of Sheffield University of Oxford

Lance Turtle Paul Klenerman Thusan DeSilva Susie Dunachie Ellie Barnes Alex Mentzer

30-40 million PBMCs from all donors sampled. Final sample sizes to be determined as part of the ISARIC-4C follow up WP9.

Internally funded by University of Liverpool and University of Oxford.

Essential data: Admission blood tests - FBC, U&Es, LFTs, CRP, Clotting function, Microbiology, SARS-CoV-2 results, influenza results (where tested) admission observations (if available). Desirable: Single set of pre-morbid blood tests values for the same parameters.

Roberta Forlano Mark Thurz Pinelopi Manousou Benjamin Mullish

Clinical data - demographics, blood test results, details regarding presentation, admission and clinical outcomes.

Imperial Biomedical Research Centre.

Raw data used to create survival from onset plot and Symptoms on presentation to hospital bar graph.

London School of Hygiene and Tropical Medicine

Fiona Woo Katherine Atkins Stephane Hue

Request for CO-CIN data. For all patients with positive SARS-CoV-2 test and viral sequence from nasal/saliva swab sample. Data variables - employed as healthcare worker, DOB/age, outer postcode, onset data, admission date, readmission?, transfer from other facility? collection date for samples, outcome and date, full lenght viral genome seq for SARS-CoV-2

Liverpool University Hospitals Foundation NHS trust and University of Liverpool

Plasma or serum (500ul). All patients fom Tier 1, or 500 approx. would require 0.5ml plasma or serum (they have 250 tier 0 patients of their own)

£20 000 funding in place for Vit D assays.

Liverpool School of Tropical Medicine

Ryan Robinson Andrea Collins

Immunosuppressive therapy duration and type, demographics, requirement for HDU/ITU admission, mortality rate and duration of inpatient stay.

Trisomy 21 Research Society

Andre Strydom Stephanie Sherman Mara Dierssen

Clinical data incl demographics, co-morbidities, medication,treatment, outcomes etc.

LuMind IDSC Foundation and other Down Syndrome organisations

10.1101/2020.11.03.20225359.

University College London

Stool samples (<0.5g) - 1000 (different subsets) and clinical metadata

Clinical data: Demographics, onset and admission, vital signs at admission, co-morbidities, daily lab results, daily treatment, pathogen testing, treatment, outcome.

Manish Kuchakulla

Clincal data: demographics, symptoms, lab values and co-morbidities.

Part internally funded, part funded by philanthropy.

Serum (250ul) maximum number available at visit 1. Clinical data - demographics, laboratory results, and outcome data.

Funding application dependent on sample approval.

Stool samples (>500mg) as early in disease matched with immunophenotyping data from ISARIC, clinical phenotype and routine lab data.

Internal funding, will apply for external funding with pilot data.

Nelson Nazareth

40 positive combined nose and throat swabs or alone. Preferably from same individual from day 1,3,9 as per protocol or 40 from day 1.

DASA accelerator COVID research program

CRN Yorkshire and Humber

Access to CRF data - specifically related to ethnicity and outcome measures

Royal Wolverhampton NHS Trust

Srinivisan Venkatachalam

Clinical characteristics of all COVID patients entered into ISARIC from The Royal Wolverhampton NHS Trust

RNA from infected tissues, throat swabs or nasal specimens, Samples from 2 patients groups: mild and severe disease outcomes (10-15 patients per group) Days 1,3,9 and 28. Associated clinical data

Funding for pilot study. Will apply for further funding with IDAMAC support.

COPD Consortium/Imperial

Paul Cullinan Chloe Bloom Brian Lipworth Thomas Drake Annemarie Docherty

All data from CRF v9.4, all admissions to date of data access; to include relevant measurements in plasma and other biosamples.

Medway NHS Foundation Trust

Site specific data from patients - demographics and all data submitted so far.

Initial review do not need funding, further funding applications if succesful.

Self-funded, will apply for further funding if succesful

West Hertfordshire Hospitals NHS Trust

Rama Vancheeswaran

Colin Berry Alex McConnachie John Cleland Antonia Ho

Queen's University Belfast

Access to 5 anonymised clinical samples (nasal/throat swabs or nasopharyngeal aspirates) from SARS-CoV-2 patients from different geographical locations. Access to 5 low passages (P4) SARS-CoV-2 strains.

UKRI/NIHR COVID-19 Rapid Response

1ug DNA per patient, capacity for over 1000 - application through GenoMICC.

Epsom & St Helier University NHS

University College London Hospital, NHS Foundation Trust

These data will be used to inform epidemiological modelling and refine model assumptions.

Andrew Bretherick, Markus Ralser, Kenneth Baillie

40ul EDTA plasma - serial samples n=300. Tier 0 data - genetic data and demographic and clinical information.

NHS Greater Glasgow & Clyde

We will produce a point of care antibody/immunoassay, building upon our recognised track record of sensitivity equivalence to ELISA demonstrated in serum and time to result <10 mins. We will translate this novel approach for use with SARS-nCoV-19 markers (indicating ongoing infection) and antibodies (indicating past infection). Within four months we will deliver a fully operational prototype validated with clinical COVID-19 samples. Importantly, we have engaged both industrial and clinical collaborators to unlock immediate validation and mass manufacture in Scotland, UK.

15 x 1ml saliva samples from COVID-19 patients. Corresponding data if possible.

Genomic DNA or cell pellets. Minimum of 300ng DNA required. Associated ISARIC clinical data

University Hospitals North Midlands NHS Trust

Compare Ct value from local laboratory database for each patient in local ISARIC-4C dataset

University of Sheffield Medical School

24ml whole blood from participants at their local site (Sheffield Teaching Hospitals NHS FT)

75 COVID 19 patients who required respiratory support, no significant comorbidities, less than 65 years of age. DNA patients aged 20-50

Anne McArdle with Ryan Thwaites

Anonymised metadata of participants including age, sex, race, and socio-economic status. Plasma samples (100ul) from up to 104 hospitalised patients for cytokine analysis using Luminex platform. These patients will be retrospectively recruited.Access to routine blood analysis if available.

UKRI funding pending. Pump-priming funds from University of Liverpool for pilot study.

Charis Pericleous

120ul of plasma from 100 ICU/HDU and 100 non-ICU/HDU COVID-19 patients from Tier 2 @ day 9 of sampling. Work can be carried out with residual samples from PO. Demographics, co-morbidities, clinical presentation, laboratory measurements, treatment outcome.

Imperial College COVID-19 FUND

Tom Beneke with Peter Openshaw & Alfredo Castello Palomares

Paired serum samples from 52 ISARIC-4C recruits where viral RNA was detected by qPCR (Ct < 37) - 140ul of each sample. If available, 20 paired plasma samples sets from COVID-naive recruits (1ml plasma each).

UKRI funding in process - as soon as confirmation received of sample access.

Viyaasan Mahalingasivam

Summary of how many patients from the ISARIC COVID cohort with/without CKD died and how many survived to discharge, stratified by other baseline characteristics.

Machine Learning and Biomarkers Group

Access to the anonymised clinical data of the ISARIC-4C study for research purposes

Edward Banham-Hall

Patients between 20-29 who died of COVID-19. Demographic data - 23 from ISARIC report

Funding pending - Wellcome Trust

A Beclere-Saclay University Hospital

Roberta Raschetti

Access to data by Swann et al. Data points: gestational age, birth weight, sex, c-section, 5min APGAR, comorbidities, DOL type of infection (congenital, intrapartum, postpartum)

National Center for Biotechnology, Madrid -Spain

Juan Manuel Luque

Genomic data (FASTQ RNA/DNA files) from COVID-19 patients and their respective clinical data.

Grant funding requested/outstanding

Department of Cardiology, Renmin Hospital of Wuhan University

Data on 35,463 patients included in the derivation dataset of 4C Score

Grants from Chinese funding bodies

Medical Schooll of Athens

The following data are requested (prioritising the first bullet):
Number of patients with Sequential Organ Failure Assessment (SOFA) score
≥2, consequent to COVID-19 infection
Number of patients with Acute Respiratory Distress Syndrome (ARDS)
Number of patients with Acute Kidney Injury
Number of patients with Acute Kidney Injury
Number of patients requiring vasopressors
Number of patients presenting coagulopathy or Disseminated Intravascular
Coagulation (DIC)
Number of patients with lactate levels >2 mmol/l
Number of patients with mental alterations
Number of patients with bilirubin levels ≥ 1.2 mg/dl or Acute Liver Dysfunction
Number of patients with SOFA score ≥2 who die within the hospital, and number of patients with SOFA score <2 who die within the hospital.

No funding is required for this work.

UCL London Hospitals NHS Foundation Trust

Jessica Manson and Professor Liz Jury

• Serum: 25 patients per group; 500ul serum sample from each at each time point: admission (baseline) and follow-up if available
• Whole blood RNA sequencing data: from 25 patients in Cohort A vs 25 patients in Cohort B.
• If RNA-seq data not available: whole blood RNA from 20 patients per group at Baseline (admission) and follow-up if available
• Accompanying clinical characterisation and laboratory data associated with the samples provided.

5/11/20 (SAMPLE)

University of Edinburgh
BHF Centre for Cardiovascular Sciences & Usher Institute

Ryan Wereski
Professor Nicholas L Mills

700 unique patient samples of frozen plasma for extraction of RNA. Alternatively, access to stored, frozen and processed RNA samples for patients would also be useful.

European Commission Horizon 2020 grant

Nahida Choudhury

Copy of uk patient data used in https://media.tghn.org/medialibrary/2020/09/ISARIC_Data_Platform_COVID-19_Report_20AUG20.pdf

Institute of Infection and Global Health, UoL

Benedict D. Michael

We request 200uL of serum from day 1, 3, or 9 from 500 patients with severe COVID-19 (WHO ordinal scale 5-7) and 500 patients with more mild disease (WHO ordinal scale 2-3).
We would intend to preferentially select those with a normal/near normal Glasgow coma score (i.e. 15/15) and compare this to those with an abnormal GCS (i.e.<15/15).

£2.3M UKRI grant to study the CNS impact of COVID-19

Stephanie Harrison

1. Anonymised data of participants (Tier Zero) including demographics, onset and admission details, vital signs at hospital admission, admission signs and symptoms, prior co-morbidities, if patient is a member of a clinically extremely vulnerable group, pre-admission medications, clinical frailty score, current medications on admission, daily treatment, daily laboratory results, pathogen testing, medications/treatment while hospitalised or on discharge, complications during hospitalisation, outcomes with dates.
2. If available, we request access to data from routine blood analysis.
3. Linked NHS COVID-19 Data Store data, including Secondary Use Services (SUS) data plus emergency care, inpatient and outpatient datasets.

Muhammad Faisal

Clare Wenham & Karen Grepin

Hospitalisation data - age and sex disaggregated.
• Demographic Data (all collected p/1 CRF)
• Onset and Admission data
• Co-morbidities (for example, gendered differences such as smoking)
• Interim/Final outcome data (p/5 CRF)

CIHR and Bill & Melinda Gates Foundation

University Hospital of Wales

Matthew Morgan

For patients only in Wales:
• 1st July - present
• Hospital in-patients with confirmed COVID19
• Reported per site in Wales
• Use of steroid by type / time started after admission
• According to ICU or non-ICU location
• According to invasive ventilation / non-invasive / HFNO / normal oxygen

People already in place through the Wales Critical Care Network

University College London

Sofia Morfopoulou

RNA-seq data from blood samples from Covid-19 patients and associated metadata (age, sex, presence of comorbities, outcome severity, day of diagnosis, day of sampling, and if follow-up is availble, presence of long-term symptoms

2 x 0.5 mL of serum from COVID-19 patients in ICU. Data would be appropriate if available.

Liverpool Centre for Cardiovascular Sciences

José Miguel Rivera-Caravaca, Prof. Gregory Lip

to information regarding comorbidities, medications (before hospitalization and during hospitalization for COVID-19, when appropriate), procedures, and lab test results of UK patients with confirmed COVID-19 infection

funding by BMS/Pfizer alliance

Data from admissions to hospital with covid-19, and patients in hospital subsequently diagnosed with covid-19. The data contained in CRFs collected at clinical trials

Internally funded. Commercial

Basque Center for Applied Mathematics

Ruben Armananzas

Anonymised clinical and laboratory parameters - demographic variables will be helpful

Active AXA Research Fund

Clinical data containing viral load, co-morbidities, and measurements for different organs for each patient

Serum - longitudinal sampling stratified according non-critical care survivors and critical care. Capacity to do 1000 samples, so 300 patients assuming 3 timepoints

Clinical data, demographic data - laboratory results, image data and patient outcomes.

Kanika Mahajan, Xifeng Yan, Richard Beswick

Patient clinical data in CRF - including demographics, vital signs, medical history, signs and symptoms, medications, clinical frailty score, treatments received, outcomes

NSF Funds: Interventional COVID-19 Response Forecasting in Local Communities Using Neural Domain Adaptation Models

RNAseq from lung or upper respiratory tract tissues from COVID patients. Also requesting data behind GenOMICC Nature paper

Approved but requires follow-up

Hong Kong Baptist University

Clnical data incl patient demographics, symptoms, comorbidities, diagnosis results, treatment methods (including medication), and related information about intensive Care and High Dependency Unit Treatments.

Leeds University Hospitals Trust

Jane Freeman, Mark Wilcox

Longitudinal faecal samples from 10 COVID positive and 10 COVID negative participants (Days 1,3, 9 and 28). Volume needed = 2mL. Accompanying clinical data for all patients/samples.

Jon Moulton Foundation, DHSC and Enterobiotix

Nottingham University Hospital

Data from the ISARIC CRF form “stroke –yes/no” and “other neurological complications – yes/no” specifically for participants from Nottingham University Hospitals for screening purposes

The Covid-19 arm of COGNID is already fully funded by the MRC

Mohamed Osman, Ingrid du Rand

Clinical Data, restricted to the data required to compute the mortality and deterioration rates as predicted by the ISARIC 4C Mortality and Deterioration calculators. This would be Tier 0 Data and would only be data collected in Wye Valley NHS Trust since the pandemic until 1rst of March

University of Liverpool,RCPCH, NHSE/I, PICANet and the NCMD

Data on children <18 years old who are SARS-CoV-2 PCR positive or who have been diagnosed clinically with MIS-C. I will require age (months), gender, ethnicity, co-morbidities, requirement for admission to critical care, requirement for invasive ventilation, administration of pharmacological therapy, requirement for inotropes, length of stay on critical care and survival/death

College of Medicine, Doha, Qatar

Tawanda Chivese

Data on age group (>40, 40-60, >60 yrs) specific number of participants with (and the totals): mortality, hospitalization, ICU, mechanical ventilation and intubation for people with HIV and those without HIV